+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Pharma's Patient Centricity

  • ID: 3783264
  • Report
  • February 2016
  • Region: Global
  • 45 Pages
  • Datamonitor Healthcare
Patient Centricity is Not a Function, but a Mindset, a New Way of Doing R&D and of Conceiving Of Therapeutic Solutions
Many in the industry agree that patient centricity is a business imperative, but it is unclear precisely what it means in business or organizational terms, and less clear still how to achieve it within the pharmaceutical industry. Patient centricity is not a function, but a mindset, a new way of doing R&D and of conceiving of therapeutic solutions.

There are multiple forces driving greater patient centricity. These include payers’ focus on outcomes, the need for product differentiation, new digital technologies and data sources, advances in genomics and personalized medicines, and the empowered consumer. But there are as many hurdles, not least the lack of a roadmap as to how to be patient-centric, the lack of standards around patient-centric data and processes, regulatory uncertainties, disciplinary silos, and engrained attitudes clinging to traditional metrics and approaches to drug development.

This report addresses:

- Drivers and resistors of patient centricity
- Patient centricity in practice
- Patient centricity impact on organizations and cultures
- Selected case studies along the value chain
Note: Product cover images may vary from those shown
Executive Summary

1. Drivers and resistors of patient centricity
2. Patient centricity in practice
3. Patient centricity means changing organizations and cultures
4. Selected case studies along the value chain

Drivers and Resistors of Patient Centricity

5. Patient centricity is more mindset than process
6. Drivers and resistors
7. Drivers
8. Resistors
9. Bibliography

Patient Centricity in Practice

10. From discovery to commercialization
11. Bibliography

Patient Centricity Means Changing Organisations and Cultures

12. New ways of thinking
13. Changing the language
14. Top-down and bottom-up leadership
15. Lessons from other industries
16. Technology enables patient centricity and demands new treatment paradigm
17. Focus on outcomes, business will follow
18. Patient centricity playbooks are emerging
19. Bibliography

Selected Case Studies Along the Value Chain

20. UCB: re-organizing around patients
21. Sanofi: diffusing patient-centric innovation
22. LEO Pharma: leading the pack in patient centricity
23. Actelion: new approaches to patient-relevant trial measures
24. AstraZeneca: engaging patients in research
25. Novo Nordisk: a patient-centric heritage
26. Shire: spreading patient centricity beyond rare diseases
27. Bibliography


28. About the author
29. Scope
30. Methodology
Note: Product cover images may vary from those shown